Neonatal Platelet Transfusion Threshold Trial (NeoPlaTT)
Thrombocytopenia (low platelet count) is common among preterm infants and may be treated with platelet transfusion. In some cases, doctors are unsure of when to treat with platelet transfusion. Platelet transfusion may prevent bleeding but may also have side effects. This study compares two commonly used platelet transfusion thresholds for extremely preterm infants with thrombocytopenia.
Purpose & Aim
Population of the study: Extremely preterm infants 23 0/7 to 26 6/7 weeks’ gestation
Intervention: Lower platelet transfusion thresholds (25×10⁹/L in first week, 20×10⁹/L thereafter) vs. higher platelet transfusion thresholds (50×10⁹/L in first week, 35×10⁹/L thereafter)
Primary Outcome: Survival without major or severe bleeding up to 40 0/7 weeks postmenstrual age
Study Information
Target Enrollment: 730
Funder: NIH NHLBI (through NICHD Neonatal Research Network)
Study Principal Investigator
Mar Romero Lopez, MD, MS, PhD
Assistant Professor
Institute for Clinical Research and Learning Health Care
Department of Pediatrics, Division of Neonatology
6431 Fannin, MSB 2.104
Houston, TX 77030
(p): 713-500-7283
[email protected]